InterCure reports NIS 130 mln revenue, NIS 12 mln positive cash flow.

• InterCure reports NIS 130 million revenue, NIS 12 million positive operating cash flow • Eleventh consecutive half with positive Adjusted EBITDA • Ongoing recovery in Israel • Recent U.S. regulatory momentum • Acquisition agreement for ISHI NEW YORK and HERZLIYA • Well-positioned to capitalize on evolving U.S. cannabis rescheduling

InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) has reported robust financial results for the first half of 2025, demonstrating resilience and sustained profitability amidst ongoing recovery efforts in Israel. The company reported NIS 130 million in revenue, an increase of 15% compared to the second half of 2024, and an increase of 3% compared to the first half of 2024 InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow^[1].

The company achieved a net loss of NIS 1.8 million, compared to near break-even in the first half of 2024, and generated NIS 12 million in positive operating cash flow, marking the eleventh consecutive half-year period of positive Adjusted EBITDA InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow^[1]. This performance underscores the strength of InterCure's vertically integrated business model and its ability to navigate challenging environments, including the impact of the October 7 attack and the ongoing war in Gaza.

InterCure has also received NIS 81 million in compensation advances from Israeli authorities for war-related damages, as part of a total submitted damages claim of NIS 251 million InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow^[1]. The company is closely monitoring regulatory developments in the U.S. regarding potential rescheduling of cannabis and believes that it is well positioned to capitalize on evolving U.S. cannabis landscape, especially following its recent signing of an agreement to acquire ISHI NEW YORK and HERZLIYA InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow^[1].

In addition to its financial performance, InterCure has also made strategic moves to expand its operations. The company resumed production, importation, and sales from the Nir Oz facility, delivering first batches since the October 7, 2023 attack and the ongoing war in Gaza. InterCure also launched more than 40 new SKUs during the first half of 2025, marking the first major product launches since October 2023 InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow^[1].

The company's acquisition agreement with ISHI NEW YORK and HERZLIYA is expected to strengthen InterCure's access to premium U.S. genetics, advanced cultivation technologies, and international market opportunities. The agreement is expected to contribute tens of millions of shekels to the company's revenues InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow^[1].

InterCure's financial performance and strategic moves position it as a strong player in the global cannabis market. However, the company faces risks and uncertainties, including changes in general economic, business, and political conditions, changes in applicable laws, and the U.S. regulatory landscape and enforcement related to cannabis InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow^[1].